ORIGINAL PAPER
Evaluation of interleukin 33 (IL-33) levels in the course of bronchial asthma (preliminary studies)
1
Collegium Medicum, Jan Kochanowski University, Kielce, Poland Head of the Collegium: Prof. Marianna Janion MD, PhD
2
Faculty of Rehabilitation, Józef Piłsudski University of Physical Education, Warsaw, Poland Head of the Department: Assoc. Prof. Edyta Smolis-Bąk
3
student, Faculty of Natural Sciences, Jan Kochanowski University, Kielce, Poland Head of the College: Dariusz Banaś PhD, Prof. JKU
4
College of Rehabilitation, Warsaw, Poland Head of the College: Prof. Jerzy Kiwerski PhD
5
Cancer Marker Department, Świętokrzyskie Ocnology Center, Kielce, Poland Head of the Department: Anna Słuszniak MD, PhD
6
Institute of Environmental Protection – National Research Institute, Warsaw, Poland Head of the Institute: Krystian Szczepański PhD
Submission date: 2023-01-05
Acceptance date: 2023-01-14
Publication date: 2023-03-31
Corresponding author
Małgorzata Anna Czarny-Działak
Małgorzata Anna Czarny-Działak PhD Collegium Medicum Jan Kochanowski University Kielce, Poland
Małgorzata Anna Czarny-Działak PhD Collegium Medicum Jan Kochanowski University Kielce, Poland
Medical Studies 2023;39(1):26-31
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Research in the field of immunology has shown a significant role of cytokines in the development of asthma, applying in particular to pro-inflammatory cytokines from Th2 lymphocytes. Interleukin 33 (IL-33) belongs to the interleukin 1 family (IL-1). It intensifies the production of cytokines by these cells. Its action induces the production of very large amounts of such cytokines as IL-4, IL-5, and IL-13, which are important in the development of allergic diseases.
Aim of the research:
An assessment of whether IL-33 levels depend on the severity of bronchial asthma in the course of the disease
Material and methods:
The study involved 80 people: 20 volunteers and 60 patients with asthma – 20 participants with mild chronic asthma, 20 with moderate, and 20 with severe asthma. All patients were subject to maintained asthma control. From each patient, blood was collected for the evaluation of IL-33 with the ELISA test; all patients had additional spirometry performed (as part of their visits to the clinic).
Results:
Elevated levels of IL-33 were found in 17 patients from the examined group of 60 people. Some volunteers, i.e. 10 out of 20, also demonstrated increased concentration of this interleukin.
Conclusions:
n our study, no specific answers have been obtained yet. The reason for the increased concentration of this cytokine in the group of volunteers is unclear. According to the medical history, these participants did not suffer from any diseases, including allergy-based. However, taking into account the prevalence of atopy in the general population (45%), it may have been people with this feature.
Research in the field of immunology has shown a significant role of cytokines in the development of asthma, applying in particular to pro-inflammatory cytokines from Th2 lymphocytes. Interleukin 33 (IL-33) belongs to the interleukin 1 family (IL-1). It intensifies the production of cytokines by these cells. Its action induces the production of very large amounts of such cytokines as IL-4, IL-5, and IL-13, which are important in the development of allergic diseases.
Aim of the research:
An assessment of whether IL-33 levels depend on the severity of bronchial asthma in the course of the disease
Material and methods:
The study involved 80 people: 20 volunteers and 60 patients with asthma – 20 participants with mild chronic asthma, 20 with moderate, and 20 with severe asthma. All patients were subject to maintained asthma control. From each patient, blood was collected for the evaluation of IL-33 with the ELISA test; all patients had additional spirometry performed (as part of their visits to the clinic).
Results:
Elevated levels of IL-33 were found in 17 patients from the examined group of 60 people. Some volunteers, i.e. 10 out of 20, also demonstrated increased concentration of this interleukin.
Conclusions:
n our study, no specific answers have been obtained yet. The reason for the increased concentration of this cytokine in the group of volunteers is unclear. According to the medical history, these participants did not suffer from any diseases, including allergy-based. However, taking into account the prevalence of atopy in the general population (45%), it may have been people with this feature.
REFERENCES (18)
1.
Gajewski P, Mejza F, Niżankowska-Mogilnicka E. Rozpoznanie i leczenie astmy u dorosłych według wytycznych GINA 2014. Med Prakt 2014; 9: 22-38.
2.
Bobrowski M, Kuna P, Pietruczuk M. Rola chemokin w astmie. J Labor Diagostics 2011; 47: 323-330.
3.
Desai D, Brightling C. Cytokine and anti-cytokine therapy in asthma: ready for the clinic? Clin Exp Immunol 2009; 158: 10-19.
4.
Seys SF, Grabowski M , Adriaensen W, Decraene A, Dilissen E, Vanoirbeek JA, Dupont LJ, Ceuppens JL, Bullens DMA. Sputum cytokine mapping reveals an‚ IL-5, IL-17A, IL-25-high’ pattern associated with poorly controlled astma. Clin Exp Allergy 2013; 9: 1009-1017.
5.
Gołąb J, Jakóbisiak M, Zagożdżon R, Obłąkowski P: Cytokiny. In: Immunologia. Gołąb J, Jakóbisiak M, Lasek (eds.) Wydawnictwo Naukowe PWN, Warszawa 2005; 198-221.
6.
Czarny-Działak MA, Słuszniak A. Assessment of concentrations of interleukin-25 in bronchial asthma – preliminary studies. Medical Studies 2016; 32: 269-273.
7.
Czyżewska-Buczyńska A, Żuk N, Romanowska-Micher- da K, Witkiewicz W. Biologiczna rola interleukiny 33 i znaczenie w patofizjologii układu sercowo-naczyniowego. Postępy Hig Med Dosw 2014; 68: 834-841.
8.
Szczepankiewicz A, Narożna B. Interleukiny w chorobach alergicznych najnowsze odkrycia genetyczne. Alergia 2013; 4: 27-28.
9.
Hardman C, Ogg G. Interleukin-33, friend and foe in type-2 immune responses. Curr Opin Immunol 2016; 42: 16-24.
10.
Chia N, Kumar RK, Foster PS, Herbert C. Enhanced proinflammatory response of macrophages to interleukin-33 in an allergic environment. Int Arch Allergy Immunol 2018; 176: 74-82.
11.
Herbert C, Do K, Chiu V, Garthwaite L, Chen Y, Young PM, Traini D, Kumar RK. Allergic environment enhances airway epithelial pro-inflammatory responses to rhinovirus infection. Clin Sci 2017; 131: 499-509.
12.
Smithgall MD, Comeau MR, Yoon BR, Kaufman D, Armitage R, Smith DE. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol 2008; 20: 1019-1030.
13.
Bourgeois E, Van LP, Samson M, Diem S, Barra A, Roga S, Gombert JM, Schneider E, Dy M, Gourdy P, Girard JP, Herbelin A. The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production. Eur J Immunol 2009; 39: 1046-1055.
14.
Milovanovic M, Volarevic V, Radosavljevic G, Jovanovic I, Pejnovic N, Arsenijevic N, Lukic ML. IL-33/ST2 axis in inflammation and immunopathology. Immunol Res 2012; 52: 89-99.
15.
Castanhinha S, Sherburn R, Walker S, Gupta A, Bossley CJ, Buckley J, Ullmann N, Grychtol R, Campbell G, Maglio- ne M, Koo S, Fleming L, Gregory L, Snelgrove RJ, Bush A, Lloyd CM, Saglani S. Pediatric severe asthma with fungal sensitization is mediated by steroid-resistant IL-33. J Allergy Clin Immunol 2015; 136: 312-322.
16.
Borish L, Steinke JW. Interleukin-33 in asthma how big of a role does it play? Curr Allergy Asthma Rep 2011; 11: 7-11.
17.
Saglani S, Lui S, Ullmann N, Campbell GA, Sherburn RT, Mathie SA, Denney L, Bossley CJ, Oates T, Walker SA, Bush A, Lloyd CM. IL-33 promotes airway remodeling in pediatric patients with severe steroid-resistant asthma. J Allergy Clin Immunol 2013; 132: 676-685.
18.
Cayrol C, Duval A, Schmitt P, Roga S, Camus M, Stella A, Burlet-Schiltz O, Gonzalez-de-Peredo A, Girard JP. Environmental allergens induce allergic inflammation through proteolytic maturation of IL-33. Nat Immunol 2018; 19: 375-385.
| eISSN: | 2300-6722 |
| ISSN: | 1899-1874 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
